about
Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV)Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivoSuppression of p75 neurotrophin receptor surface expression with intrabodies influences Bcl-xL mRNA expression and neurite outgrowth in PC12 cellsEfficient production of soluble recombinant single chain Fv fragments by a Pseudomonas putida strain KT2440 cell factoryRise and fall of an anti-MUC1 specific antibodyIdentification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatusFructose 1,6-Bisphosphate Aldolase, a Novel Immunogenic Surface Protein on Listeria SpeciesBacterial flagellar capping proteins adopt diverse oligomeric states.On the influence of vector design on antibody phage displayThe production of a genus-specific recombinant antibody (scFv) using a recombinant potyvirus protease.Multimerization domains for antibody phage display and antibody production.Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque originPhage display vectors for the in vitro generation of human antibody fragments.Mating antibody phage display with proteomics.Perspectives for systematic in vitro antibody generation.Enrichment of open reading frames presented on bacteriophage M13 using hyperphage.High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.Selection of recombinant antibodies from antibody gene libraries.SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli.Identification of immunogenic polypeptides from a Mycoplasma hyopneumoniae genome library by phage display.Phage display derived therapeutic antibodies.Affinity maturation by phage display.Improved microtitre plate production of single chain Fv fragments in Escherichia coli.Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity.Towards proteome scale antibody selections using phage display.Obtention and engineering of non-human primate (NHP) antibodies for therapeutics.Human-like antibodies neutralizing Western equine encephalitis virus.Generating recombinant antibodies to the complete human proteome.Construction of human antibody gene libraries and selection of antibodies by phage display.Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium.A human scFv antibody generation pipeline for proteome research.Novel human recombinant antibodies against Mycobacterium tuberculosis antigen 85BDelivery of antibodies to the cytosol: debunking the myths.Identification of immunogenic proteins and generation of antibodies against Salmonella Typhimurium using phage display.Human antibodies targeting CD30(+) lymphomas.Construction of human naive antibody gene libraries.Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.Recombinant antibody fragments allow repeated measurements of C-reactive protein with a quartz crystal microbalance immunosensor.High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells.Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies.
P50
Q27486900-8364B7CB-9D12-4F3C-8A24-32875EE54F41Q28483998-3F871828-9347-4276-995E-5B5201B7452BQ28574351-7DA42F96-EEE3-44F9-8A14-BCAD708D4B3BQ28742082-2B61DB09-0B8A-45A9-9192-99605D18AD64Q28743508-68B92937-89A4-4387-8A97-FECC6F17BE66Q28752041-26492083-7796-4B38-95D1-A37030CEB93CQ28831319-6CB3D1C6-E6C8-44DA-B27E-F49070B7170FQ30275690-8BE75769-9F85-43B7-BE00-292DA10B9BDFQ30826435-311B6657-122D-4055-AA67-263B61FC0305Q30865607-5F31292A-0977-46E8-88BA-6F38EE2974FAQ30871071-EAA2DD5D-1BBD-43E9-949E-05B776F96983Q31042202-50A3D0A6-F35E-469B-8222-CEEE91841173Q31135881-A2280FFC-3E98-4EEB-96AB-3EFB6ABF2F1CQ33196204-E5F54D41-47FB-4F47-9065-18529A4B5908Q33222408-C7B4A614-5F99-4349-BE64-DBF2463C2EABQ33258277-5B33E8B9-5E3F-46A8-A08D-E2BD4689D8EFQ33285349-806C1DF0-EA8F-413A-92DC-9552595DBB7AQ33322074-FB60B520-9770-46EA-AB95-E82A56EDFDA6Q33337825-1D8FB9CC-E44D-4EA4-89FE-CDF1344C07E7Q33352725-0AF16393-1F7C-4D5D-90EB-254BB43CA6E4Q33392248-DAA8FD5F-C89B-41D4-905E-2B2C17FDD08CQ33413793-EC438C87-32A9-4D32-910E-1C3939E9C91EQ33474206-E8642B57-B9A6-47C7-80AA-BCE4ECE922D8Q33476009-5694C9A5-9C98-4548-9F95-34010D13BAE3Q33514574-3695A3FF-23BD-4557-B43B-E5ACA218ACCFQ33526822-36FB83A8-7579-4A56-880F-5CDB7D4C0551Q33573599-60CD7F20-A428-49CA-8B36-2509363A2F4FQ33600779-5E4CEA7F-4BBA-4A78-BEAB-4DBF98515BB5Q33649975-9C20E769-B6B3-427D-A452-855E8CF2FA01Q33657809-79EAC79B-48BA-4899-AB13-57B0425E3F18Q33706675-CB8BF01C-B80A-486A-B614-66B90C3110ECQ33994150-A507B378-4CFB-4CBA-ABEB-1A20A8725E68Q34223983-250C25F4-870F-4FFC-9E80-1A9FED1D3EB8Q34306479-26B1B9C8-F7DC-4B66-A8EF-1CDF661F8D35Q34376854-38352273-CA50-4001-9328-EDA588C49B68Q34386022-AD1972CC-5FEC-4F5C-8436-A1D3DAA49D23Q34488183-5492814C-2BC1-411B-AC95-043A90D1EA84Q34503854-6C7072FD-65DF-4F94-BA73-396292A7CECEQ34784806-8B737F6C-F6D2-44B8-865C-FF50CDF4034EQ34889730-07AF6561-42FF-40F1-94D0-790BF375FE11
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Michael Hust
@ast
Michael Hust
@en
Michael Hust
@es
Michael Hust
@nl
Michael Hust
@pt
Michael Hust
@sl
type
label
Michael Hust
@ast
Michael Hust
@en
Michael Hust
@es
Michael Hust
@nl
Michael Hust
@pt
Michael Hust
@sl
prefLabel
Michael Hust
@ast
Michael Hust
@en
Michael Hust
@es
Michael Hust
@nl
Michael Hust
@pt
Michael Hust
@sl
P108
P214
P244
P106
P1153
7004145140
P21
P214
P244
n2018182924
P31
P496
0000-0003-3418-6045
P735
P7859
lccn-n2018182924